Why I'm Writing The Recio Brief

I spent last Tuesday morning in a cardiac OR running anesthesia on an 82-year-old getting an aortic valve replacement. By the afternoon I was on the phone with a broker about a specialty RCM company doing $1.4M in EBITDA in the Southeast.

Most people who do one of those things never do the other.

That gap is why I'm writing this.

The discourse has a hole in it

There's no shortage of writing about healthcare. There's no shortage of writing about acquisitions, private equity, AI, or wealth-building. What's missing is the writing that sits at the intersection of all of them, written by someone who is actually in the rooms.

The search fund operator writing on LinkedIn has rarely diligenced a clinical asset.

The longevity influencer has rarely managed a hemodynamically unstable patient on three pressors at 3 a.m.

I'm not claiming to be the only person who can synthesize across these domains. I'm claiming that the synthesis is undersupplied, and that the operators and allocators I respect most are hungry for it.

What this is

The Recio Brief is the writing I wished existed when I was building this thing. It covers four pillars:

Acquisitions and Capital. Search fund mechanics, SBA financing, sector spotlights on the sub-segments most searchers ignore (toxicology labs, bioanalytical services, specialty RCM, behavioral health, the boring beautiful businesses that compound), operator playbooks from the 100-day mark and beyond.

Healthcare and Medicine. Where AI is actually working in clinical settings versus where it's vaporware. The economics of ASCs and ambulatory infusion centers. New medical advancements and what they mean for operators, not just for the journals. Healthcare marketing as a moat. Neuroscience and anesthesia for the curious.

Wealth, Strategy, and Sovereignty. Entity architecture, trust structures, the boring infrastructure that compounds across generations. Public equities and macro through the lens of allocation, not prediction. Family governance.

The Operator's Edge. What I'm reading. What I'm using. What jiu-jitsu, high-performance driving, and CQB training have taught me about decision-making under load. The cool stuff that doesn't fit elsewhere but earns its place because it sharpens the operator.

Plus three cross-cutting beats: a Regulatory Pulse covering the policy shifts that actually move outcomes, a Toolstack breakdown of what I'm running my holdco on, and The Read, a quarterly list of the books and papers worth your time.

What this is not

It's not investment advice. Nothing here will ever solicit private investment or recommend a trade. When I write about a sub-sector my acquisition platform is bidding in, I'll disclose it.

It's not patient anecdotes. Anything clinical is composite, anonymized, and used only when the lesson outweighs the story.

It's not hype. I have nothing to sell you. The Brief is free, and it will stay free for the foreseeable future. There may be a paid tier eventually for deal teardowns and quarterly letters, but the core argument and analysis stay open.

What I'm asking of you

Read the first three or four essays before you decide whether to keep reading. The first sector piece lands this week: The RCM Bottleneck: Why Specialty Revenue Cycle Is the Most Mispriced Acquisition Lane in Healthcare.

If it earns your time, stay. If it doesn't, the unsubscribe link works on every email and I won't take it personally.

For those who do stay: I want to hear what you're working on. The best writing is shaped by the readers it's written for. My inbox is open.

The Recio Brief is for the people building things at the intersection nobody is writing from. The first issue lands shortly.

Dr. Jesus Recio